- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05765110
SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease (EMO-SPEECH-PD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease (PD) affects mobility (motor function), thought processes (cognition) and mood (emotion). The language is one of the most complex programs in humans. It contains information about mobility, thinking and mood at the same time. These three levels of agility, thinking and mood are subject to spontaneous fluctuations and can be influenced by external stimuli such as pictures that induce emotions. In addition, these three levels are influenced on the one hand by Parkinson's disease itself, and on the other hand by its treatment with medication or with deep brain stimulation (DBS). For this reason, the investigators would like to investigate language in Parkinson's disease patients in a very detailed computerized way for motor, cognitive and emotional elements for better management of therapies.
With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect fluctuations in motor, mood, and thinking in Parkinson's disease patients.
Even in healthy subjects, speech changes in a situational manner, due to which the investigators will also include healthy subjects as a control group.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mario Sousa, MD
- Phone Number: +41 31 664 23 49
- Email: mario.sousa@insel.ch
Study Contact Backup
- Name: Paul Krack, Prof.
- Phone Number: +41 31 66 4 03 71
- Email: paul.krack@insel.ch
Study Locations
-
-
-
Prague, Czechia, 166 27
- Active, not recruiting
- Czech Technical University Prague
-
-
-
-
-
Bern, Switzerland, 3010
- Recruiting
- University Hospital Inselspital, Berne
-
Contact:
- Mario Sousa, MD
- Phone Number: +41 31 664 23 49
- Email: mario.sousa@insel.ch
-
Contact:
- Paul Krack, Prof.
- Phone Number: +41 31 66 4 03 71
- Email: paul.krack@insel.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients with Parkinson's Disease
Inclusion Criteria:
- Written informed consent
- Idiopathic PD according to the Movement Disorders Society Criteria;
- Age of participants > 30 and ≤ 75 years;
- Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;
- Fluent in German or French
Exclusion Criteria:
- Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);
- Clinical diagnosis of aphasia;
- Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).
- Cognitive impairment (Montreal Cognitive Assessment (MoCa) < 24/30 points);
- Depression with acute suicidal ideation
Healthy Controls
Inclusion Criteria:
- Written informed consent
- Adults from 50-70 years old;
- Fluent in German or French
Exclusion Criteria:
- Diagnosis of Parkinson's disease;
- Cognitive impairment (Montreal Cognitive Assessment (MoCa) < 24/30 points);
- Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.);
- Clinical diagnosis of aphasia, dysarthria, and stuttering;
- Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Parkinson's disease patients with DBS
All Parkinson's disease patients with bilateral deep brain stimulation (DBS) in the subthalamic nucleus
|
Experiment will be performed without dopaminergic medication
Turning off the stimulation during experiment
Experiment will be performed with dopaminergic medication
Experiment will be performed with stimulation (ON condition)
|
Experimental: Parkinson's disease patients without DBS
All Parkinson's disease patients without bilateral deep brain stimulation (DBS) in the subthalamic nucleus
|
Experiment will be performed without dopaminergic medication
Experiment will be performed with dopaminergic medication
|
No Intervention: Healthy Controls
All healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients
Time Frame: Visit 2 (< 3 months)
|
A speech analyser software will allow extraction of basic motor acoustic speech features.
The extracted variables that better index the dopaminergic medication or stimulation motor effect assessed with Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III - motor score [0-132 pts.] will be used as primary outcomes in this part.
Higher scores in MDS-UPDRS part III means more severe motor symptoms.
|
Visit 2 (< 3 months)
|
Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients
Time Frame: Visit 2 (< 3 months)
|
A speech analyser software will allow extraction of basic acoustic speech features.
For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality.
The extracted variables that better index the dopaminergic medication or stimulation emotional effect assessed with Neuropsychiatric fluctuations scale (NFS) [0-60 pts.] will be used as primary outcomes in this part.
Higher scores in NFS means more severe neuropsychiatric fluctuations.
|
Visit 2 (< 3 months)
|
Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients
Time Frame: Visit 2 (< 3 months)
|
A speech analyser software will allow extraction of basic acoustic speech features.
For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality.
The extracted variables that better index the dopaminergic medication or stimulation cognitive effect assessed with verbal fluency task will be used as primary outcomes in this part.
Higher scores in Fluency task means better outcome.
|
Visit 2 (< 3 months)
|
Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients
Time Frame: Visit 2 (< 3 months)
|
A speech analyser software will allow extraction of basic acoustic speech features.
For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality.
The extracted variables that better index the dopaminergic medication or stimulation cognitive effect assessed with Stroop test will be used as primary outcomes in this part.
Higher scores in Stroop test means worse outcome.
|
Visit 2 (< 3 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dyskinesia severity
Time Frame: At visit 1 (baseline) and visit 2 (< 3 months)
|
Score on Marconi dyskinesia rating scale [0-28 pts.].
Higher scores in Marconi dyskinesia rating scale means more severe dyskinesia.
|
At visit 1 (baseline) and visit 2 (< 3 months)
|
Momentary mood state
Time Frame: At visit 1 (baseline) and visit 2 (< 3 months)
|
Score on Visual Analogue Mood Scale (VAMS) [0-100 pts.].
Higher scores in VAMS means better mood.
|
At visit 1 (baseline) and visit 2 (< 3 months)
|
Momentary anxiety state
Time Frame: At visit 1 (baseline) and visit 2 (< 3 months)
|
Score on Visual Analogue Anxiety Scale (VAAS) [0-100 pts.].
Higher scores in VAAS means more anxiety.
|
At visit 1 (baseline) and visit 2 (< 3 months)
|
Bradyphrenia assessment
Time Frame: At visit 1 (baseline) and visit 2 (< 3 months)
|
Score on Bradyphrenia scale [0-72 pts.].
Higher scores in Bradyphrenia scale means more severe bradyphrenia.
|
At visit 1 (baseline) and visit 2 (< 3 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of non-motor aspects of experiences of Daily Living
Time Frame: < 2 weeks from the baseline visit
|
Score on MDS-UPDRS parts I [0-52 pts.].
Higher scores in MDS-UPDRS-part I scale means more severe non-motor symptoms on experiences of Daily Living
|
< 2 weeks from the baseline visit
|
Severity of motor aspects of experiences of Daily Living
Time Frame: < 2 weeks from the baseline visit
|
Score on MDS-UPDRS parts II [0-52 pts.].Higher scores in MDS-UPDRS-part II scale means more severe motor symptoms on experiences of Daily Living
|
< 2 weeks from the baseline visit
|
Severity of motor fluctuations
Time Frame: < 2 weeks from the baseline visit
|
Score on MDS-UPDRS parts IV [0-24 pts.].
Higher scores in MDS-UPDRS-part IV scale means more severe motor fluctuations
|
< 2 weeks from the baseline visit
|
Quality of life assessment
Time Frame: < 2 weeks from the baseline visit
|
Score on Parkinson's Disease Questionnaire, 8 items (PDQ-8) [0-32 pts.].
Higher scores in PDQ-8 scale means worse quality of life
|
< 2 weeks from the baseline visit
|
Dysarthria severity assessment
Time Frame: < 2 weeks from the baseline visit
|
Score on Voice Handicap Index (VHI) [0-120 pts.].
Higher scores in VHI scale means more severe dysarthria (speech impairment)
|
< 2 weeks from the baseline visit
|
Anxiety and depressive symptomatology
Time Frame: < 2 weeks from the baseline visit
|
Score on Hospital Anxiety and Depression Scale (HADS) [0-60 pts.].
Higher scores in HADS scale means more severe anxiety and depressive symptoms
|
< 2 weeks from the baseline visit
|
Apathetic symptomatology
Time Frame: < 2 weeks from the baseline visit
|
Score on Starkstein Apathy Scale (SAS) [0-42 pts.].
Higher scores in SAS scale means more severe apathetic symptoms
|
< 2 weeks from the baseline visit
|
Impulse-control disorders assessment
Time Frame: < 2 weeks from the baseline visit
|
Score on Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale (QUIP-RS) [0-112 pts.].
Higher scores in QUIP-RS scale means more severe impulsive-compulsive disorders
|
< 2 weeks from the baseline visit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Paul Krack, Prof., University Hospital Inselspital, Berne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Cardiotonic Agents
- Dopamine Agents
- Sympathomimetics
- Dopamine
- Dopamine Agonists
Other Study ID Numbers
- 2022-01304
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Dopaminergic OFF drug state
-
University Hospital Inselspital, BerneUniversity Hospital, Geneva; Ecole Polytechnique Fédérale de LausanneRecruiting
-
University Hospital Inselspital, BerneCzech Technical University in PragueRecruitingParkinson DiseaseSwitzerland, Czechia
-
University of BirminghamCompletedHyperglycemia | Aerobic Exercise | Glucose Metabolism Disorders (Including Diabetes Mellitus)United Kingdom
-
Abramson Cancer Center at Penn MedicineRecruiting
-
Brigham and Women's HospitalNational Institutes of Health (NIH); Atrius HealthCompletedAging | Adverse Drug Event | Benzodiazepine Sedative Adverse Reaction | Anticholinergic Adverse ReactionUnited States
-
University Hospital, GenevaRecruitingParkinson DiseaseSwitzerland
-
James LiaoRecruitingDisease Progression | Parkinson Disease | Gait Disorders, Neurologic | Deep Brain Stimulation | Accidental Fall | Subthalamic NucleusUnited States
-
China National Center for Cardiovascular DiseasesUnknown
-
Virginia Commonwealth UniversityRecruitingHeart Failure | Heart DysfunctionUnited States
-
University Hospital Schleswig-HolsteinMichael J. Fox Foundation for Parkinson's ResearchRecruitingDystonia | Parkinson | Dystonia, Familial | DYT3 | DYT5 | PINK1 Gene DeletionGermany